Gastroesophageal Reflux Disease With Dyspepsia Symptoms Clinical Trial
Official title:
Takepron Specified Drug-use Survey "Gastroesophageal Reflux Disease With Dyspepsia Symptoms"
To evaluate the efficacy of 4-week lansoprazole (Takepron) therapy for subjective symptomatic improvement in gastroesophageal reflux disease patients with dyspepsia symptoms
This is a special drug use surveillance of lansoprazole (Takepron) with a 4-week
observational period, designed to evaluate the efficacy in gastroesophageal reflux disease
patients with dyspepsia symptoms (planned sample size, 15000).
The dosage regimen is as follows:
- For reflux esophagitis, the usual adult dosage is 30 mg of lansoprazole administered
orally once daily for up to 8 weeks. For maintenance treatment of repeatedly
recurring/relapsing reflux esophagitis, the dosage is 15 mg of lansoprazole
administered orally once daily. If insufficient efficacy is observed, the dosage may be
increased to 30 mg administered orally once daily.
- For non-erosive gastroesophageal reflux disease, the usual adult dosage is 15 mg of
lansoprazole administered orally once daily for up to 4 weeks.
;
Observational Model: Cohort, Time Perspective: Prospective